Flow cytometric analysis of 4% PFA fixed and Fixation/Permeabilization solution permeabilized Human PBMC (human peripheral blood mononuclear cells), stimulated 6h with 50 ng/ml PMA and 1 μg/ml Ionomycin and the last 4 hours with 1μg/ml BFA (Right panel) or untreated (Left panel) labelling APC-Cy7 Mouse anti-Human CD4 and Alexa Fluor® 488 Mouse Anti-Human IL-22 Antibody at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | IL-22 |
| Synonyms | Interleukin-22; Cytokine Zcyto18; IL-10-related T-cell-derived-inducible factor (IL-TIF); ILTIF; ZCYTO18; IL22 |
| Location | Secreted |
| Accession | Q9GZX6 |
| Clone Number | S-3255 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | ICFCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 488 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ICFCM | 5μl per million cells in 100μl volume | Hu |
Background
Interleukin-22 (IL-22) is a 20 kDa α-helical cytokine of the IL-10 family that is produced chiefly by activated innate lymphoid cells, Th17, Th22 and γδ T cells, signals exclusively through a heterodimeric receptor complex of IL-22R1 and IL-10R2 to activate STAT3 and, to a lesser extent, STAT1 and STAT5, and functions as a frontline defender of barrier organs by up-regulating antimicrobial peptides (e.g., β-defensins, RegIIIγ), mucins and tight-junction proteins, stimulating epithelial proliferation and survival, while simultaneously suppressing inflammatory cytokine release from tissue-resident immune cells, thereby orchestrating tissue repair, containment of commensal microbes and protection against extracellular bacterial and fungal pathogens; however, its dysregulation contributes to psoriasis, inflammatory bowel disease, fibrosis and certain cancers, making it a key target for therapeutic modulation.
Picture
Picture
FC
